IBD NC 2018
(O1) Risk of cancer in paediatric onset inflammatory bowel disease: A nationwide cohort study 1977-2014
(O2) THE TLR9 AGONIST COBITOLIMOD INDUCES ANTI-INFLAMMATORY EFFECTS AND BALANCES TH17/T-REG CELL RESPONSES IN ULCERATIVE COLITIS
(O3) Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on SWIBREG
(O4) Increasing abundance of Faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn’s disease
(O5) The impact of thiopurines on the natural history and surgical outcome of ulcerative colitis.
(P1) Lost in translation of transition?
(P2) Development of a systematic transition eHealth program: “Here we are – Here we come”
(P3) Childhood onset IBD has a more severe disease course compared to adulthood onset
(P4) FMT capsules improve symptoms and decrease Fecal Calprotectin in Ulcerative Colitis patients
(P5) Hypersensitivity reactions to intravenous iron are rare in clinical practice
(P6) Clinical effectiveness of golimumab: interim analysis of the GO-SWIBREG study
(P7) Calprotectin in saliva as a biomarker of disease activity in inflammatory bowel disease
(P8) Examining the validity of the IBD-Fatigue Scale in Sweden
(P9) Monitoring of calprotectin levels in IBD patients with point-of-care test CalproSmart
(P10) Clinical effectiveness of vedolizumab in patients with Crohn’s disease: interim analysis of the SVEAH study
(P11) Clinical effectiveness of vedolizumab in patients with ulcerative colitis: interim analysis of the SVEAH study
(P12) Incidence, prevalence, and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study